What question did this study set out to answer?

To evaluate the effectiveness of Vykat XR in treating hyperphagia among individuals with Prader-Willi syndrome.

April 5, 2026Annals of Medicine and Surgery0 citationsOpen Access

Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader–Willi syndrome

PPPrakriti PokhrelLarkin Community Hospital HNHidhaya S. NoorulStanley Medical College LFLaraib FatimaDow University of Health Sciences

Key Points

To evaluate the effectiveness of Vykat XR in treating hyperphagia among individuals with Prader-Willi syndrome.
Evaluation of FDA approvals for new treatments
Focus on patient demographics (aged 4 years and older)
Assessment of unmet needs in treatment options
Vykat XR is the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome
Approval provides a new pharmacologic option for managing hyperphagia
Addresses long-standing needs of patients and caregivers in this population

Abstract

On March 27, 2025, the U.S. Food and Drug Administration (FDA) approved Vykat XR (diazoxide choline-extended release tablets) for the treatment of hyperphagia in individuals aged 4 years and older with Prader–Willi Syndrome (PWS). This marks the first FDA-approved pharmacologic therapy targeting hyperphagia in this population, addressing a long-standing unmet need and offering new hope for patients, caregivers, and clinicians.

AI에게 질문

Bookmark

View Full Paper